Harbour BioMed is an innovative global biopharmaceutical firm. It specializes in advanced antibody therapies for immunology and oncology. Recently, HBM announced a critical strategic advance in its relationship with AstraZeneca. Their collaboration dates from March 2025 and continues to grow. Both companies wish to develop next-generation biotherapeutics, including antibody drug conjugates (ADCs) and T cell engagers.
Under the new terms of the collaboration, AstraZeneca can select discovery programs per year for the next four consecutive years. Overall, this reflects the growing momentum and trust in the partnership. AstraZeneca also has the option to license selected programs for further development. Harbour BioMed is entitled to receive option fees, milestone payments upon development and commercialization, and also tiered royalties based on future net sales. These financial arrangements are in line with the original framework of the collaboration.
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: “We are pleased to advance our collaboration with AstraZeneca to develop next-generation biotherapeutics in oncology. Harbour BioMed has collaborated with AstraZeneca on multiple programs since 2022, and over time, the two parties have established a trusted and solid partnership. With our strong capabilities enabled by our proprietary antibody platforms, we’re well positioned to support AstraZeneca in developing innovative biotherapeutics that can address significant unmet medical needs and improve patient outcomes globally.”
Also Read: LabConnect & OmniScience launch agentic AI for trial data
This expanded collaboration reflects Harbour BioMed’s strong commitment to developing new therapies. It also reflects AstraZeneca’s confidence in HBM’s unique platforms and scientific expertise. Collectively, they seek to accelerate the discovery of innovative oncology treatments that could improve care for patients around the world.
